Latest Idenix Pharmaceuticals (IDIX) Headlines
Post# of 4
Posted On: 03/13/2014 9:43:02 AM
Latest Idenix Pharmaceuticals (IDIX) Headlines
Uptrend Call Working As Idenix Pharmaceuticals Stock Rises 49.8% (IDIX)
Comtex SmarTrend(R) - Mon Mar 10, 11:04AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 49.83% as of today's recent price of $6.63.
Idenix Pharmaceuticals Up 51.0% Since SmarTrend Uptrend Call (IDIX)
Comtex SmarTrend(R) - Mon Mar 03, 9:41AM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 50.96% as of today's recent price of $6.68.
Idenix Q4 Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:39PM CST
Idenix Pharmaceuticals Inc. (IDIX) reported a loss of 21 cents per share in the fourth quarter of 2013, wider than the year ago loss of 17 cents per share but narrower than the Zacks Consensus Estimate loss of 22 cents.
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the year ended December 31, 2013.
Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present at the Cowen & Company 34 Annual Health Care Conference on Wednesday, March 5, 2014, at 8:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA. Management will also present at the Barclays Capital Global Healthcare Conference on Thursday, March 13, 2014, at 9:30 a.m. Eastern Time at the Loews Hotel in Miami, FL.
Amerigo Announces 2013 Financial Results
Marketwire - Wed Feb 26, 6:32AM CST
Amerigo Resources Ltd. (TSX: ARG) ("Amerigo" or the "Company") reported today results for the year ended December 31, 2013.
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Shares of IDIX Up 56.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 24, 9:18AM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 56.16% as of today's recent price of $6.91.
The Zacks Analyst Blog Highlights: Sanofi, Regeneron Pharmaceuticals, United Therapeutics, Medivation and Idenix Pharmaceuticals
PR Newswire - Fri Feb 21, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report), United Therapeutics Corporation (Nasdaq:UTHR-Free Report), Medivation, Inc. (Nasdaq:MDVN-Free Report) and Idenix Pharmaceuticals Inc. (Nasdaq:IDIX-Free Report).
3 Biotech Stocks to Bet on this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
It is not too late to join the biotech bandwagon.
Idenix Pharmaceuticals Shares Up 55.5% Since SmarTrend's Buy Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Feb 14, 4:48PM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 3 months, Idenix Pharmaceuticals has returned 55.48% as of today's recent price of $6.88.
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Idenix Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 7:30AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will participate in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 10:45 a.m. Eastern Time at the Waldorf Astoria Hotel in New York, NY.
Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:43AM CST
The shares of Genomic Health Inc. fell nearly 9% on the day.This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.This medical research company has seen a flat track record when it comes to current year estimate revisions.
Medical Marijuana Industry Continues Rapid Expansion As Leaders Acquire New Dispensary Sites
PR Newswire - Wed Feb 05, 8:02AM CST
Alternative care pioneers continue to grow market with increasing demand: Zoned Properties[SM], Inc. (OTC: ZDPY), GW Pharmaceuticals plc (NASDAQ: GWPH), Growlife, Inc. (OTCBB: PHOT), Medbox, Inc. (OTC: MDBX) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX)
After a Strong December, LCD Panel Market to Moderate in Q1
M2 - Tue Feb 04, 8:58AM CST
The market for large-sized liquid-crystal display (LCD) panels is set for a moderate seasonal decline in the first quarter after a busy end-of-year in 2013 that saw record shipments for TV and tablet panels, according to a new report from IHS Technology (NYSE: IHS).
Gilead Sciences, Inc. Earnings: Will Sovaldi Send Shares Soaring?
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 04, 7:30AM CST
Gilead Sciences will release its quarterly report on Tuesday, and investors are still riding high as the biotech stock kept climbing in January -- after doubling in 2013. But even as the company celebrates success in the hepatitis C space that...
This Week in Biotech: Let's Get Clinical!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 01, 12:08PM CST
With the SPDR S&P Biotech Index up 58% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Uptrend Call Working As Idenix Pharmaceuticals Stock Rises 49.8% (IDIX)
Comtex SmarTrend(R) - Mon Mar 10, 11:04AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 49.83% as of today's recent price of $6.63.
Idenix Pharmaceuticals Up 51.0% Since SmarTrend Uptrend Call (IDIX)
Comtex SmarTrend(R) - Mon Mar 03, 9:41AM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 50.96% as of today's recent price of $6.68.
Idenix Q4 Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:39PM CST
Idenix Pharmaceuticals Inc. (IDIX) reported a loss of 21 cents per share in the fourth quarter of 2013, wider than the year ago loss of 17 cents per share but narrower than the Zacks Consensus Estimate loss of 22 cents.
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the year ended December 31, 2013.
Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present at the Cowen & Company 34 Annual Health Care Conference on Wednesday, March 5, 2014, at 8:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA. Management will also present at the Barclays Capital Global Healthcare Conference on Thursday, March 13, 2014, at 9:30 a.m. Eastern Time at the Loews Hotel in Miami, FL.
Amerigo Announces 2013 Financial Results
Marketwire - Wed Feb 26, 6:32AM CST
Amerigo Resources Ltd. (TSX: ARG) ("Amerigo" or the "Company") reported today results for the year ended December 31, 2013.
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Shares of IDIX Up 56.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 24, 9:18AM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 4 months, Idenix Pharmaceuticals has returned 56.16% as of today's recent price of $6.91.
The Zacks Analyst Blog Highlights: Sanofi, Regeneron Pharmaceuticals, United Therapeutics, Medivation and Idenix Pharmaceuticals
PR Newswire - Fri Feb 21, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report), United Therapeutics Corporation (Nasdaq:UTHR-Free Report), Medivation, Inc. (Nasdaq:MDVN-Free Report) and Idenix Pharmaceuticals Inc. (Nasdaq:IDIX-Free Report).
3 Biotech Stocks to Bet on this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
It is not too late to join the biotech bandwagon.
Idenix Pharmaceuticals Shares Up 55.5% Since SmarTrend's Buy Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Feb 14, 4:48PM CST
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 3 months, Idenix Pharmaceuticals has returned 55.48% as of today's recent price of $6.88.
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Idenix Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 7:30AM CST
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will participate in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 10:45 a.m. Eastern Time at the Waldorf Astoria Hotel in New York, NY.
Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:43AM CST
The shares of Genomic Health Inc. fell nearly 9% on the day.This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.This medical research company has seen a flat track record when it comes to current year estimate revisions.
Medical Marijuana Industry Continues Rapid Expansion As Leaders Acquire New Dispensary Sites
PR Newswire - Wed Feb 05, 8:02AM CST
Alternative care pioneers continue to grow market with increasing demand: Zoned Properties[SM], Inc. (OTC: ZDPY), GW Pharmaceuticals plc (NASDAQ: GWPH), Growlife, Inc. (OTCBB: PHOT), Medbox, Inc. (OTC: MDBX) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX)
After a Strong December, LCD Panel Market to Moderate in Q1
M2 - Tue Feb 04, 8:58AM CST
The market for large-sized liquid-crystal display (LCD) panels is set for a moderate seasonal decline in the first quarter after a busy end-of-year in 2013 that saw record shipments for TV and tablet panels, according to a new report from IHS Technology (NYSE: IHS).
Gilead Sciences, Inc. Earnings: Will Sovaldi Send Shares Soaring?
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 04, 7:30AM CST
Gilead Sciences will release its quarterly report on Tuesday, and investors are still riding high as the biotech stock kept climbing in January -- after doubling in 2013. But even as the company celebrates success in the hepatitis C space that...
This Week in Biotech: Let's Get Clinical!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 01, 12:08PM CST
With the SPDR S&P Biotech Index up 58% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
(0)
(0)Idenix Pharmaceuticals (IDIX) Stock Research Links
Scroll down for more posts ▼